Adagene Inc. (ADAG)
1.78
0.00 (0.00%)
At close: Jan 14, 2025, 3:58 PM
1.80
1.12%
After-hours Jan 14, 2025, 03:59 PM EST
undefined% (undefined)
| Bid | 0.73 |
| Market Cap | 78.80M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.72 |
| PE Ratio (ttm) | -2.47 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.5 |
| Volume | 8,466 |
| Avg. Volume (20D) | 63,852 |
| Open | 1.88 |
| Previous Close | 1.78 |
| Day's Range | 1.78 - 1.88 |
| 52-Week Range | 1.74 - 4.38 |
| Beta | undefined |
About ADAG
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical tr...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 9, 2021
Employees 174
Stock Exchange NASDAQ
Ticker Symbol ADAG
Website https://www.adagene.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ADAG stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 180.90% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
4 months ago ·
Source
+8.86%
Adagene shares are trading higher after the compan...
Unlock content with
Pro Subscription
